{"pmid":32379296,"title":"Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19).","text":["Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19).","JAMA Pediatr","Hwang, Thomas J","Randolph, Adrienne G","Bourgeois, Florence T","32379296"],"journal":"JAMA Pediatr","authors":["Hwang, Thomas J","Randolph, Adrienne G","Bourgeois, Florence T"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379296","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1001/jamapediatrics.2020.1888","topics":["Treatment"],"weight":1,"_version_":1666597097274605568,"score":9.490897,"similar":[{"pmid":32459832,"title":"Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.","text":["Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.","Pediatric patients are excluded from most COVID-19 therapeutic trials. We outline a rationale for the inclusion of children in COVID-19 therapeutic trials with enabled us to include children of all ages in a therapeutic COVID-19 trial at our institution.","Clin Infect Dis","Raabe, Vanessa N","Lighter, Jennifer","Caplan, Arthur L","Ratner, Adam J","32459832"],"abstract":["Pediatric patients are excluded from most COVID-19 therapeutic trials. We outline a rationale for the inclusion of children in COVID-19 therapeutic trials with enabled us to include children of all ages in a therapeutic COVID-19 trial at our institution."],"journal":"Clin Infect Dis","authors":["Raabe, Vanessa N","Lighter, Jennifer","Caplan, Arthur L","Ratner, Adam J"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459832","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/cid/ciaa656","keywords":["covid-19","sars-cov-2","clinical trial","ethics","pediatrics"],"topics":["Treatment"],"weight":1,"_version_":1668141322625613825,"score":45.027706},{"pmid":32296817,"pmcid":"PMC7184504","title":"Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials.","text":["Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials.","Investigators are employing unprecedented innovation in the design of clinical trials to rapidly and rigorously assess potentially promising therapies for COVID-19; this is in stark contrast to the continued near universal regressive practice of exclusion of pregnant and breastfeeding women from these trials. The few trials which allow their inclusion focus on post-exposure prophylaxis or outpatient treatment of milder disease, limiting the options available to pregnant women with severe COVID-19 to compassionate use of remdesivir, or off-label drug use of hydroxychloroquine or other therapies. These restrictions were put in place despite experience with these drugs in pregnant women. In this Viewpoint, we call attention to the need and urgency to engage pregnant women in COVID-19 treatment trials now in order to develop data-driven recommendations regarding the risks and benefits of therapies in this unique but not uncommon population.","Clin Infect Dis","LaCourse, Sylvia M","John-Stewart, Grace","Adams Waldorf, Kristina M","32296817"],"abstract":["Investigators are employing unprecedented innovation in the design of clinical trials to rapidly and rigorously assess potentially promising therapies for COVID-19; this is in stark contrast to the continued near universal regressive practice of exclusion of pregnant and breastfeeding women from these trials. The few trials which allow their inclusion focus on post-exposure prophylaxis or outpatient treatment of milder disease, limiting the options available to pregnant women with severe COVID-19 to compassionate use of remdesivir, or off-label drug use of hydroxychloroquine or other therapies. These restrictions were put in place despite experience with these drugs in pregnant women. In this Viewpoint, we call attention to the need and urgency to engage pregnant women in COVID-19 treatment trials now in order to develop data-driven recommendations regarding the risks and benefits of therapies in this unique but not uncommon population."],"journal":"Clin Infect Dis","authors":["LaCourse, Sylvia M","John-Stewart, Grace","Adams Waldorf, Kristina M"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296817","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1093/cid/ciaa444","keywords":["covid-19","pregnancy","treatment","trial"],"e_drugs":["remdesivir","Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138493302079490,"score":41.161858}]}